Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in human hepatocellular and gastric cancer xenografts

In Vivo

Volumn 15, Issue 3, 2001, Pages 185-193

  Teicher, B A ^a   Menon, K ^a   Alvarez, E ^a   Shih, P L C ^a   Faul, M M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antiangiogenic agent; Gastric cancer xenograft; Hepatocellular carcinoma xenograft; Intratumoral vessels; Protein Kinase C (PKC )

Indexed keywords

31765; CD31 ANTIGEN; FLUOROURACIL; GEMCITABINE; HYDROCHLORIC ACID; PROTEIN KINASE C BETA INHIBITOR; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG;

AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EXPOSURE; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; SCHOOL CHILD; STOMACH CANCER; TREATMENT OUTCOME; TUMOR XENOGRAFT;

EID: 0034888620     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Natural killer cell activity depression in peripheral blood and ascites from gastric cancer patients with high TGF-β1 expression
2. Primary Neoplasms of the Liver
3. The hepatitis B virus X protein enhances the DNA binding potential and transcription efficacy of bZip transcription factors
4. High prevalence of hepatitis C virus infection in schistosomiasis japanica patients associated with hepatocellular carcinoma
5. Hepatocellular carcinoma: From gene to public health
6. Treatment of Hepatocellular carcinoma
7. Hepatitis B virus x antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma
8. Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies
9. Angiogenesis: New aspects relating to its initiation and control
10. Angiogenesis in cancer, vascular, rheumatoid and other disease
11. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease
12. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: Single agent and combination chemotherapy studies
13. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
14. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin
15. Markers of tumor angiogenesis: Clinical applications in prognosis and anti-angiogenic therapy
16. What, if anything, is an angiogenic factor?
17. Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications
18. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth
19. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation
20. The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLCgamma
21. VEGF receptor signaling in tumor angiogenesis
22. The role of protein kinase C in the regulation of cell growth and in signalling to the cell nucleus
23. Multiple biological response activated by nuclear protein kinase C
24. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 elucidation of their importance in receptor activation and signal transduction
25. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C
26. Inhibitors of protein kinase C and related receptors for the lipophilic second-messenger sn-1,2-diaclyglycerol
27. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h] [1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531), and related analogues: Isozyme selective inhibitors of protein kinase C beta
28. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531
29. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and supressed by an orally effective beta-isoform-selective inhibitor
30. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor
31. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis
32. The Jak/Stat signaling cascade
33. Antiangiogenic effects of a protein kinase Cβ selective small molecule
34. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line
35. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen
36. Altered regulation of Src tyrosine kinase by transforming growth factor β1 in a human hepatoma cell line
37. Growth and hepatospecific gene expression of human hepatoma cells in a defined medium
38. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice
39. In vitro properties of epithelial cell lines established from human carcinomas and nonmalignant tissue
40. Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-beta levels after treatment with radiation or cyclophoshamide in the rat 13762 mammary carcinoma
41. Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma
42. Neoangiogenesis and relationship to nuclear p53 accumulation and vascular endothelial growth factor expression in advanced gastric carcinoma
43. The expression of vascular endothelial growth factor and proliferative activity of cancer cells in gastric cancer
44. Intratumoral neovascularization and growth pattern in eariy gastric carcinoma
45. Four resections for hepatic metastasis gastric cancer: Histochemical analysis of cell proliferation, apoptosis and angiogenesis
46. The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma
47. Effect of host microenvironment on the micro-circulation of human colon adenocarcinoma
48. Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis
49. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors
50. The expression of thymidine phosphorylase and its correlation with angiogenesis in gastric adenocarcinoma
51. The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluoroucil derivatives in advanced gastric carcinoma
52. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer
53. Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma
54. Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma
55. Vascular endothelial growth factor/vascular permeability factor mRNA expression in patients with chronic hepatitis C and hepatocellular carcinoma
56. Microvessel density of hepatocellular carcinoma: Its relationship with prognosis
57. Vascular changes in hepatocellular carcinoma: Correlation of radiologic and pathologic findings
58. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma
59. A systems approach to cancer therapy